LoginRegister

    Sun Pharma Advanced Research Company Q2 loss widens to Rs 63 cr

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    New Delhi: Sun Pharma Advanced Research Company (SPARC) on Monday reported a net loss of Rs 63.16 crore for the quarter ended September 30 of the ongoing fiscal. The company had reported a loss of Rs 2.58 crore for July-September, 2018-19.


    Read Also: Sun Pharma launches Drizalma Sprinkle in US for treating neuro-psychiatric and pain disorders in patients with swallowing difficulties


    Total income declined to Rs 19.45 crore during the second quarter as compared with Rs 65.92 crore in the year-ago period, SPARC said in a regulatory filing.


    Read Also: FIRST: Sun Pharma unveils dry-eye treatment drug CEQUA in US

    pharmapharma companypharma newsSPARCSun PharmaSun Pharma Advanced Research Companysun pharma reported loss
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X